Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

CMPX

Compass Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1738021Held by 5 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.0M
Net Income FY2025
$(66.0M)
EPS (Basic, as reported)
$-0.42
Net Margin FY2025
—
ROE FY2025
-33.8%
Total Equity
$197.0M
Shares Out
180M
Business description

Compass Therapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 0
Fiscal yearFY2018FY2019FY2020FY2021⚑FY2022FY2023FY2024FY2025
Revenue—————010
Research & development—(22)(15)——(38)(42)(56)
General & administrative—0(13)(11)(12)(12)(15)(17)
Total operating expenses—(34)(28)(82)(42)(50)(57)(73)
Operating income—0(28)(82)(42)(50)(57)(73)
Interest expense—0(1)00———
Interest & investment income—1002876
Other income (expense), net—(1)(2)02876
Pre-tax income—(35)(29)(82)(39)(42)——
Income tax expense—0000000
Net income—0(29)(82)(39)(42)(49)(66)
EPS — basic———($1.31)($0.37)($0.33)($0.36)($0.42)
Shares outstanding — basic (M)———63105127137158
Shares outstanding — diluted (M)——————137—
  • ⚑ Weighted-average shares changed ×1.67 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.